Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 51407-837

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 51407-837). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-836-05lb (Lurasidone HCI)

Label for Lurasidone Hydrochloride 20 mg film-coated tablets by Golden State Medical Supply, Inc. The label shows a supply of 500 tablets with NDC 51407-836-05. It includes directions for storage at controlled room temperature and instructions to dispense in a child-resistant container. The label is marked Rx Only and features a barcode and the GSMS incorporated logo.*

FDA Label Image

51407-837-05lb (Lurasidone HCI)

Lurasidone Hydrochloride 60 mg film-coated tablets packaging label. The label includes the NDC number 51407-837-05, indicates the quantity of 500 tablets, and states Rx Only. It features dosage details, storage instructions at 20°-25°C, and a barcode. Marketed by GSMS, Incorporated, Camarillo, CA.*

FDA Label Image

51407-838-05lb (Lurasidone HCI)

Label for Lurasidone Hydrochloride tablets 120 mg by Golden State Medical Supply, Inc. The label states the dosage strength and instructs pharmacists to dispense the medication guide to patients. It mentions the package contains 500 film-coated tablets for oral use, with storage instructions and child-resistant container precautions. A barcode and QR code are also visible.*

FDA Label Image

Avetlogo-mg (Avetlogo mg)

FDA Label Image

Avet-logo (Avet Logo)

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of Lurasidone Hydrochloride, showing its molecular connectivity including multiple rings and heteroatoms, consistent with the active ingredient in the drug product.*

FDA Label Image

Figure-1 (Figure 1)

A pharmacokinetics impact chart showing the fold change and 90% confidence intervals of lurasidone drug levels (Cmax and AUC) when co-administered with other drugs. The chart includes strong and moderate CYP3A4 inhibitors (Ketoconazole, Diltiazem) and strong CYP3A4 inducers (Rifampin) plus Lithium, illustrating changes relative to lurasidone alone on the horizontal axis.*

FDA Label Image

Figure-2 (Figure 2)

A forest plot displaying fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax, AUC, Ctrough) for various interacting drugs relative to the interactive drug alone. The drugs include P-gp substrates (Digoxin 0.25 mg SD), CYP3A4 substrates (Midazolam 5 mg SD), oral contraceptives (Ethinyl Estradiol, Norelgestromin), and Lithium 600 mg BID. The X-axis shows change relative to the interactive drug alone ranging from -1.0 to 1.0.*

FDA Label Image

Figure-3 (Figure 3)

A plot depicting fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of Lurasidone Hydrochloride relative to reference values. The chart compares results across renal impairment categories (mild, moderate, severe), hepatic impairment categories (mild, moderate, severe), and population descriptions by gender (females) and race (Asian). Values are shown with error bars indicating variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.